Precision Psychiatry Market is expected to reach $1,727.4 Million by 2026

The healthcare experts have found the precision psychiatry market to be one of the most rapidly evolving and dynamic markets, and the global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.

The BIS Research report on the global precision psychiatry market segments the market on the basis of:

· Product Type (products and services)

· Biomarker (genetic biomarkers and protein biomarkers)

· Sample (blood and non-blood)

· Technology (sequencing, polymerase chain reaction, microarray, immunoassay, liquid chromatography-mass spectrometry, and other technologies)

· Application (Alzheimer’s disease, Parkinson’s disease, autism, depression, schizophrenia, bipolar disorder, and other applications)

· End User (hospitals and diagnostic laboratories, academic and research institutes, and other end users)

· Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World).

Key Questions Answered in this Report:

•   How is precision psychiatry revolutionizing the field of mental health diagnostics?
•   What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?
•   What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?
•   How is the COVID-19 pandemic impacting the global precision psychiatry landscape?
•   What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
•   What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?
•   What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
•   How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o   Product Type (Products and Services)
o   Sample (Blood-Based and Non-Blood-Based)
o   Biomarker (Genetic Biomarkers and Protein)
o   Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others)
o   Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others)
o   End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others)
o   Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
•   What are the growth opportunities for the companies in the region of their operation?
•   Who are the leading players with significant offerings in the global precision psychiatry market?
•   Which companies are anticipated to be highly disruptive in the future, and why?
•   What are the current unmet needs that are being faced in the global precision psychiatry market?

Request a Sample - https://bisresearch.com/requestsample?id=1086&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: • Industry Analysis ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog